News GSK makes fresh neuroscience foray with £2bn+ ABL deal Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting.
News Epsilogen buys rival cancer antibody firm TigaTx Epsilogen has bought TigaTx, pooling their resources to create what it says will be a leader in 'pan-isotope' cancer antibodies.
News Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug Buoyed by data from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's drug from its Brainshuttle programme.
News MoonLake secures $500m for lead drug, plus other financings MoonLake secures $500m in financing for lead inflammatory disease drug sonelokimab while AIRNA, Atsena, and Neurona complete $100m+ private rounds.
News Lilly throws lifeline to Sangamo with $1.4bn licensing deal A $1.4 billion gene therapy alliance with Eli Lilly has come at an opportune time for Sangamo as its cash reserves start to dry up.
News BeiGene abandons TIGIT antibody after lung cancer flop BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.